APO-ATAZANAVIR atazanavir 300 mg (as sulfate) capsule blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

atazanavir sulfate, Quantity: 341.7 mg (Equivalent: atazanavir, Qty 300 mg)

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

formulario farmacéutico:

Capsule

Composición:

Excipient Ingredients: lactose monohydrate; sodium starch glycollate type A; purified water; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; iron oxide red; Gelatin; iron oxide black; sodium lauryl sulfate

Vía de administración:

Oral

Unidades en paquete:

30's

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Atazanavir is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents. ,This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies

Resumen del producto:

Visual Identification: Hard gelatin capsules with red opaque cap and blue opaque body, imprinted APO on cap and A300 on body in black ink, filled with almost white granules; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius

Estado de Autorización:

Registered

Fecha de autorización:

2018-05-14